Santhera Pharmaceuticals Holding AG (SWX:SANN)
14.80
-0.48 (-3.14%)
Apr 29, 2025, 5:31 PM CET
SWX:SANN Revenue
In the year 2024, Santhera Pharmaceuticals Holding AG had annual revenue of 39.12M CHF, down -62.17%. Santhera Pharmaceuticals Holding AG had revenue of 14.11M in the half year ending June 30, 2024, with 125.82% growth.
Revenue
39.12M
Revenue Growth
-62.17%
P/S Ratio
4.77
Revenue / Employee
869.27K
Employees
45
Market Cap
186.41M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 39.12M | -64.30M | -62.17% |
Dec 31, 2023 | 103.41M | 95.94M | 1,283.84% |
Dec 31, 2022 | 7.47M | 9.07M | -568.53% |
Dec 31, 2021 | -1.60M | -16.60M | -110.63% |
Dec 31, 2020 | 15.01M | -60.37M | -80.09% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 62.40B |
Novartis AG | 46.87B |
Lonza Group AG | 6.57B |
Alcon | 8.98B |
Galderma Group AG | 4.02B |
Straumann Holding AG | 2.50B |
Sandoz Group AG | 9.41B |
Sonova Holding AG | 3.71B |
Santhera Pharmaceuticals Holding AG News
- 7 weeks ago - Santhera Pharmaceuticals reports FY results - Seeking Alpha
- 3 months ago - Santhera Pharmaceuticals Provides Update on Royalty Agreement for AGAMREE® (Vamorolone) and Warrants held by Idorsia - GlobeNewsWire
- 4 months ago - Santhera Enters into Supply and Distribution Agreement for AGAMREE® (Vamorolone) with Clinigen Group - GlobeNewsWire
- 5 months ago - Santhera Announces Approval from China's NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy - Benzinga
- 8 months ago - Santhera Pharmaceuticals reports 1H results - Seeking Alpha
- 8 months ago - Santhera Enters into an Exclusive Distribution Agreement with GENESIS Pharma for AGAMREE® (Vamorolone) in Central and Eastern Europe - GlobeNewsWire